Eisai Co (ESALF) Company Description: Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the ...

In a statement, the FDA said this is the first time it has authorised an over-the-counter (OTC ... That feature is also under review by the FDA. Eisai has retreated from the optimistic view ...

In collaboration with the University of Kentucky and Eisai Co (OTC:ESAIY). Ltd., a Phase IIb clinical trial for a novel treatment for vivax malaria is set to begin. Furthermore, the company ...

Phenylephrine started to be used in OTC decongestants after manufacturers ... driving up healthcare costs. Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease ...

Biogen and Eisai's Leqembi received US Food and Drug ... as well as potential in lupus, should help counter this threat to the profit share. In addition, Biogen receives substantial (more than ...

The Consumer Health segment markets nonprescription over-the-counter medicines, medical products ... The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback ...

STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...

TOKYO, Nov 5, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a ...

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

OTC is one of the fastest growing energy and commodities brokerage firms, with global operations across North America, Europe, and Asia. Its brokerage services include crude and refined products ...